Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
8,040 SEK | 0,00% |
|
-8,74% | 0,00% |
11/02 | Saniona AB - Special Call | |
10/02 | Saniona's partner Medix dient definitieve aanvraag in voor tesofensine in Mexico | FW |
Beschrijving van de bedrijfsactiviteiten: SANA AB
Aantal werknemers: 22
Verdeling van verkoop per activiteit: SANA AB
Start boekjaar: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Biotechnology | 2,66 mln. | 8,2 mln. | 10,48 mln. | 15,28 mln. | 16,84 mln. |
Geografische uitsplitsing van de verkoop: SANA AB
Start boekjaar: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Germany | - | - | - | - | 8,72 mln. |
United Kingdom | - | - | - | - | 7,49 mln. |
Denmark | - | - | - | - | 633K |
Other European Countries | 2,66 mln. | 6,23 mln. | 7,97 mln. | 11,52 mln. | - |
The Americas | - | 1,97 mln. | 2,5 mln. | 3,76 mln. | - |
Managers: SANA AB
Directeur | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Feldthus
CEO | Algemeen Directeur | 65 | 30-04-2022 |
Hoofd Techniek/Wetenschap/O&O | 67 | 01-01-2014 | |
Anita Milland
DFI | Financieel Directeur/CFO | 57 | 30-04-2020 |
Karin Nielsen
CTO | Hoofd Techniek/Wetenschap/O&O | 55 | 30-04-2022 |
Hoofd Techniek/Wetenschap/O&O | 66 | 01-05-2020 |
Besturend: SANA AB
Bedrijfsleider | Titel | Leeftijd | Van |
---|---|---|---|
Jørgen Drejer
CHM | Voorzitter | 70 | 30-04-2022 |
Directeur/Bestuurslid | 67 | 01-01-2015 | |
Anna Ljung
BRD | Directeur/Bestuurslid | 45 | 19-01-2018 |
Directeur/Bestuurslid | 59 | 01-01-2023 |
Bedrijfsgegevens: SANA AB

Bedrijven van de groep: SANA AB
Naam | Categorie en sector |
---|---|
Saniona A/S
![]() Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Biotherapeutische geneesmiddelen
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Varia. 1j. | Varia. 3j. | Kapi.($) | |
---|---|---|---|---|---|---|
0,00% | -8,74% | +235,00% | +3,74% | 84,63 mln. | ||
-0,77% | -2,20% | +8,72% | +94,68% | 118 mld. | ||
-0,10% | -5,13% | -28,95% | +6,77% | 72,09 mld. | ||
+0,99% | -2,85% | +69,94% | +143,36% | 38,79 mld. | ||
-2,40% | +1,89% | +30,72% | -27,59% | 28,73 mld. | ||
+2,38% | +3,29% | +55,74% | +4,84% | 24,63 mld. | ||
+4,77% | +7,13% | +17,32% | -36,23% | 23,61 mld. | ||
-2,06% | +6,27% | +321,50% | +903,29% | 15,76 mld. | ||
+0,81% | -0,80% | +168,76% | +230,46% | 14,19 mld. | ||
+0,53% | +9,49% | -19,23% | -31,04% | 13,46 mld. | ||
Gemiddelde | +0,42% | +0,77% | +85,95% | +129,23% | 34,92 mld. | |
Gewogen gemiddelde per kap. | +0,09% | -0,69% | +33,05% | +93,83% |
- Beurs
- Aandelen
- Koers SANION
- Onderneming SANA AB